Skip to main
NUVL

Nuvalent (NUVL) Stock Forecast & Price Target

Nuvalent (NUVL) Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 47%
Buy 53%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Nuvalent Inc. is positioned favorably within the biopharmaceutical landscape, particularly through its promising product candidates, NVL-520 and NVL-655, each showing deep and durable antitumor responses with improved tolerability, which may reshape the existing treatment paradigm for non-small cell lung cancer (NSCLC) and tap into a projected peak revenue opportunity exceeding $3.6 billion. The company stands to benefit from a shift in the standard of care, bolstered by updated NCCN guidelines that improve detection of ROS1 fusions, potentially enhancing market penetration against established therapies such as Alecensa and Lorbrena, which are projected to generate substantial revenues by 2025. Additionally, the anticipated performance of NVL-330, alongside favorable data from ongoing studies, suggests an increasing probability of success and an expansion of the addressable market for targeted therapies, reinforcing the positive outlook on Nuvalent's stock potential.

Bears say

Nuvalent Inc faces significant challenges that contribute to a negative outlook on its stock, primarily due to potential issues surrounding its product candidates' safety profiles and efficacy. Concerns regarding adverse events related to its drugs, such as neurological side effects and suboptimal safety in ongoing trials, could limit clinical uptake and hinder regulatory approvals. Additionally, unforeseen delays in research and development, as well as intense competition in the ALK and ROS1 non-small cell lung cancer market, could pose substantial risks to the company's commercialization prospects and its ability to secure necessary funding.

Nuvalent (NUVL) has been analyzed by 15 analysts, with a consensus rating of Buy. 47% of analysts recommend a Strong Buy, 53% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nuvalent and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nuvalent (NUVL) Forecast

Analysts have given Nuvalent (NUVL) a Buy based on their latest research and market trends.

According to 15 analysts, Nuvalent (NUVL) has a Buy consensus rating as of Mar 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $135.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $135.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nuvalent (NUVL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.